Neurocrine Biosciences Reports Second Quarter 2015 Results
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 8/21/2026
- Wall Street sinks as bond yields rise, Walmart results disappoint
- Walmart shares fall despite earnings beat
- Alibaba stock dips as Q2 profit misses estimates despite strong AI cloud growth
- Wolfe remains "broadly bullish on AI semis stocks", names Top Pick
- Moderna stock pulls back after massive one-day rally: analysts weigh in
- Wall Street sinks as bond yields rise, Walmart results disappoint
- Wolfe remains "broadly bullish on AI semis stocks", names Top Pick
- Supermicro probe finds no senior management link to export violations
- SpaceX shares fall as second lockup period ends
- Hertz Global amends voting agreement with CK Amarillo after lawsuit
Catalyst-Rich 6 Months Ahead for Neurocrine Bio. (NBIX), Cowen Notes
July 30, 2015 9:53 AM EDTCowen analyst Phil Nadeau reiterated an Outperform rating and boosted his price target on Neurocrine Bio. (NASDAQ: NBIX) to $55.00 (from $45.00), saying the company is gearing up for a catalyst-rich 6 months.
Nadeau commented, "NBIX's pipeline should yield a number of catalysts over the next 6... More
Neurocrine Biosciences (NBIX) Tops Q2 EPS by 1c
July 29, 2015 5:30 PM EDTNeurocrine Biosciences (NASDAQ: NBIX) reported Q2 EPS of ($0.28), $0.01 better than the analyst estimate of ($0.29).
For earnings history and earnings-related data on Neurocrine Biosciences (NBIX) click here.
... More
